Oncology
Excerpt from the Press Release: PHILADELPHIA, April 20, 2021 /PRNewswire/ — A trans-Atlantic collaborative group of researchers led by Children’s Hospital of Philadelphia (CHOP) has received approximately $680,000 from a group of research charities led by Solving Kids’ Cancer UK to study slowly progressive, or “indolent,” neuroblastoma, which does not respond to chemotherapy and lacks other treatment options. The grant will fund…
Excerpt from the Press Release: REDWOOD CITY, Calif., April 21, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced dosing of the first patient in a multicenter Phase 1/1b clinical trial evaluating RMC-5552, the company’s investigational…
Excerpt from the Press Release: NEWTOWN, Pa., April 22, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced today that the first patient has been dosed in an investigator-initiated Phase 2 study to assess the efficacy and safety of rigosertib…
Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–Apr. 22, 2021– DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the launch of DermTech PLAplusTM, its next generation test for the enhanced early detection of melanoma. PLAplusdelivers objective and actionable information to guide clinical management decisions…
Excerpt from the Press Release: NEEDHAM, Mass.–(BUSINESS WIRE)–Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has completed enrollment for its Phase 1 clinical trial in patients with newly diagnosed high-grade glioma to evaluate the safety and efficacy of CAN-2409 in combination with immune checkpoint inhibitor Opdivo® (nivolumab) and…
Excerpt from Press Release: REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxel/cisplatin as first-line treatment for patients with advanced…
Excerpt from the Press Release: BOSTON, April 15, 2021 /PRNewswire/ — NanoView Biosciences Inc. (“NanoView”), a leading biomarker characterization company in the emerging field of extracellular vesicle biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center (“BIDMC”) to study the involvement of biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy (“ICIT”) for…
Excerpt from the Press Release: SAN FRANCISCO, April 8, 2021 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics…
Excerpt from the Press Release: SAN DIEGO, March 30, 2021 /PRNewswire/ — HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab),…
Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Mar. 31, 2021– Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for advanced renal cell carcinoma (RCC). This approval allows for the marketing of CABOMETYX in combination with…